Small Molecules

25 Jun 2017 Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association
25 Jun 2017 Verastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association
25 Jun 2017 Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
23 Jun 2017 European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
23 Jun 2017 AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma
23 Jun 2017 Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients
23 Jun 2017 Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23 Jun 2017 ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
23 Jun 2017 Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer
23 Jun 2017 Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting
23 Jun 2017 Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix® (vortioxetine) sNDA
23 Jun 2017 Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
23 Jun 2017 Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23 Jun 2017 Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
23 Jun 2017 Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis
23 Jun 2017 AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
23 Jun 2017 AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European Hematology Association (EHA) Annual Congress
22 Jun 2017 Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China
22 Jun 2017 Phase 2 Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder
22 Jun 2017 Eisai Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study will Continue as Planned Based on Interim Safety Analysis by Independent Data Monitoring Committee (DMC)
22 Jun 2017 Lipocine Validates "No Titration" Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate
21 Jun 2017 InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod
21 Jun 2017 Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference
21 Jun 2017 eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer
21 Jun 2017 Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing